Carlos GOMEZ ROCA - Thèse en cours

Adresse Professionnelle
1 avenue Irène Joliot Curie 31059
TOULOUSE FRANCE
gomez-roca.carlos@iuct-oncopole.fr
cgomezroca@yahoo.com
Identifiant ORCID 0000000280432529

Expérience professionnelle :
CDI depuis le 1 novembre 2013
Domaine d'activité : Oncologie
Type de contrat : Professions libérales
Fonction exercée : Praticien Specialiste des CLCC
Secteur d'emploi : Santé et action sociale
Unité de recherche ou entreprise : Institut Claudius Regaud http://www.iuct-oncopole.fr
Toulouse - FRANCE

Doctorat Cancérologie

- Université de Toulouse

Ecole doctorale : BSB - Biologie, Santé, Biotechnologies

Sujet : Complexité immune du microenvironnement tumoral dans les localisations primitives et métastatiques du cancer du colon et son impact sur la réponse à l’immunothérapie

Mots-clés de la thèse : Tumeur primitive,Metastases,microenvironnement immun,immunothérapie,cancer colorectal,

Direction de thèse : Maha AYYOUB

Co-direction de thèse : Christel DEVAUD

Unité de recherche : CRCT - Centre de Recherches en Cancérologie de Toulouse UMR 1037
Intitulé de l'équipe : T2i - Immunité antitumorale et immunothérapie

Médecine - Diplome d'Université Cancerologie Clinique

obtenu en novembre 2007 - Université Paris-Saclay
Option : Cancerologie Clinique

Production scientifique

- Aurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, Céline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montane, Anne-Sophie Bidaux, Isabelle Treilleux, Lauriane Eberst, Catherine Terret, Iphigénie Korakis, Gwenaelle Garin, David Pérol, Jean-Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier-Caux, Nathalie Bendriss-Vermare, Philippe Cassier 2024. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers Science Translational Medicine, 16, https://hal.science/hal-04645010v1
- Feliu V, Gomez-Roca C, Michelas M, Thébault N, Lauzéral-Vizcaino F, Salvioni A, Scandella L, Sarot E, Valle C, Balança CC, Scarlata CM, Delord JP, Ayyoub M, Devaud C. 2023. Distant antimetastatic effect of enterotropic colon cancer-derived α4β7+CD8+ T cells. Science Immunology, 8(84):eadg8841, https://www.science.org/doi/10.1126/sciimmunol.adg8841?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
- Francois-Xavier Danlos, Matthieu Texier, Bastien Job, Severine Mouraud, Lydie Cassard, Capucine Baldini, Andrea Varga, Andrey Yurchenko, Audrey Rabeau, Stephane Champiat, Diane Letourneur, Delphine Bredel, Sandrine Susini, Yuna Blum, Aurelien Parpaleix, Cedric Parlavecchio, Lambros Tselikas, Jean-Eudes Fahrner, Anne-Gaelle Goubet, Mathieu Rouanne, Saloomeh Rafie, Alae Abbassi, Ines Kasraoui, Marie Breckler, Siham Farhane, Samy Ammari, Salim Laghouati, Anas Gazzah, Ludovic Lacroix, Benjamin Besse, Nathalie Droin, Marc Deloger, Sophie Cotteret, Julien Adam, Laurence Zitvogel, Sergey Nikolaev, Nathalie Chaput, Christophe Massard, Jean-Charles Soria, Carlos Gomez-Roca, Gerard Zalcman, David Planchard, Aurelien Marabelle 2023. Genomic Instability and Pro-Tumoral Inflammation are associated with Primary Resistance to Anti-PD1 + Anti-Angiogenesis in Malignant Pleural Mesothelioma Cancer Discovery, pp.OF1-OF22, https://univ-rennes.hal.science/hal-03972355v1
- François-Xavier Danlos 1 2 3, Matthieu Texier 4, Bastien Job 5, Severine Mouraud 2, Lydie Cassard 6, Capucine Baldini 1, Andrea Varga 1, Andrey A Yurchenko 7, Audrey Rabeau 8, Stéphane Champiat 1 2, Diane Letourneur 2 9, Delphine Bredel 2, Sandrine Susini 2, Yuna Blum 10, Aurelien Parpaleix 11, Cedric Parlavecchio 11, Lambros Tselikas 2 3 12, Jean-Eudes Fahrner 2, Anne-Gaelle Goubet 2 3, Mathieu Rouanne 2 3, Saloomeh Rafie 1, Alae Abbassi 1, Ines Kasraoui 13, Marie Breckler 14, Siham Farhane 1, Samy Ammari 13, Salim Laghouati 15, Anas Gazzah 1, Ludovic Lacroix 16, Benjamin Besse 17, Nathalie Droin 14, Marc Deloger 5, Sophie Cotteret 18, Julien Adam 19, Laurence Zitvogel 2 3, Sergey I Nikolaev 7, Nathalie Chaput 6 20, Christophe Massard 1, Jean-Charles Soria 21, Carlos Gomez-Roca 8, Gerard Zalcman 22, David Planchard 17, Aurelien Marabelle 1 2 3 2023. Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma Cancer Discovery, 13(4):858-879., https://aacrjournals.org/cancerdiscovery/article/13/4/858/725020/Genomic-Instability-and-Protumoral-Inflammation
- Ortiz-Muñoz G, Brown M, Carbone CB, Pechuan-Jorge X, Rouilly V, Lindberg H, Ritter AT, Raghupathi G, Sun Q, Nicotra T, Mantri SR, Yang A, Doerr J, Nagarkar D, Darmanis S, Haley B, Mariathasan S, Wang Y, Gomez-Roca C, de Andrea CE, Spigel D, Wu T, Delamarre L, Schöneberg J, Modrusan Z, Price R, Turley SJ, Mellman I, Moussion C. 2023. In situ tumour arrays reveal early environmental control of cancer immunity. Nature, 618(7966):827-833, https://www.nature.com/articles/s41586-023-06132-2
- Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle Ray-Coquard, Christelle De La Fouchardière, François Bertucci, Anthony Gonçalves, Carlos Gomez-Roca, Benoit You, Valéry Attignon, Sandrine Boyault, Philippe Cassier, Armelle Dufresne, Séverine Tabone-Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaël Garin, Jeanyves Blay, David Pérol 2023. Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort Cancers, 15, https://hal.science/hal-04209734v1
- Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Luis Perez Gracia J, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. 2022. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. J Immunoth Cancer, May;10(5):e004076. , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114963/
- Benoit Rousseau, Ivan Bieche, Eric Pasmant, Nadim Hamzaoui, Nicolas Leulliot, Lucas Michon, Aurelien de Reynies, Valerie Attignon, Michael Foote, Julien Masliah-Planchon, Magali Svrcek, Romain Cohen, Victor Simmet, Paule Augereau, David Malka, Antoine Hollebecque, Damien Pouessel, Carlos Gomez-Roca, Rosine Guimbaud, Amandine Bruyas, Marielle Guillet, Jean-Jacques Grob, Muriel Duluc, Sophie Cousin, Christelle de la Fouchardiere, Aude Flechon, Frederic Rolland, Sandrine Hiret, Esma Saada-Bouzid, Olivier Bouche, Thierry Andre, Diane Pannier, Farid El Hajbi, Stephane Oudard, Christophe Tournigand, Jean-Charles Soria, Stephane Champiat, Drew Gerber, Dennis Stephens, Michelle Lamendola-Essel, Steven Maron, Bill Diplas, Guillem Argiles, Asha Krishnan, Severine Tabone-Eglinger, Anthony Ferrari, Neil Segal, Andrea Cercek, Natalie Hoog-Labouret, Frederic Legrand, Clotilde Simon, Assia Lamrani-Ghaouti, Luis Diaz, Pierre Saintigny, Sylvie Chevret, Aurelien Marabelle 2022. PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Cancer Discovery, 12, pp.1435-1448, https://hal.science/hal-04210180v1
- Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, Thibault Mazard, Carlos Gomez-Roca, Jean-Philippe Metges, Carine Bellera, Antoine Adenis, Iphigenie Korakis, Pierre-Guillaume Poureau, Kevin Bourcier, Maud Toulmonde, Michele Kind, Christophe Rey, Celine Auzanneau, Alban Bessede, Isabelle Soubeyran, Antoine Italiano 2022. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial European Journal of Cancer, 162, pp.161-169, https://hal.science/hal-03723894v1
- Stefan Bissinger, Carina Hage, Vinona Wagner, Ilona-Petra Maser, Verena Brand , Martina Schmittnaegel, Anna-Maria Jegg, Michael Cannarile, Carl Watson, Irina Klaman, Natascha Rieder, Alejandra González Loyola, Tatiana V Petrova, Philippe A Cassier, Carlos Gomez-Roca, Vincent Sibaud, Michele De Palma, Sabine Hoves, Carola H Ries 2021. Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition Sci Transl Med, 2021 Jun 16;13(598):eabd4550, https://pubmed.ncbi.nlm.nih.gov/34135110/
- Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub 2021. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells JCI Insight, 6, https://hal.science/hal-03365487v1
- Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini 5, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub 2021. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells JCI Insight, 2021 Jan 25;6(2):e142513, https://pubmed.ncbi.nlm.nih.gov/33332284/
- Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, Philippe Aftimos, Nadine Houédé, Céleste Lebbé, Celine Pages, Thierry Lesimple, Monica Dinulescu, Jan Schellens, Suzanne Leijen, Sylvie Rottey, Vibeke Kruse, Richard Kefford, Sandrine Faivre, Carlos Gomez-Roca, Armin Scheuler, Giorgio Massimini, Eric Raymond 2021. Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors Targeted Oncology, 16, pp.37-46, https://hal.umontpellier.fr/hal-03617763v1
- Thomas Aparicio, Nathalie Cozic, Christelle de La Fouchardière, Emeline Meriaux, Jérome Plaza, Laurent Mineur, Rosine Guimbaud, Emmanuelle Samalin, Florence Mary, Thierry Lecomte, Carlos Gomez-Roca, Paul-Arthur Haineaux, Alain Gratet, Jannick Selves, Yves Menu, Nikias Colignon, Laetitia Johnson, Frédéric Legrand, Gilles Vassal 2021. The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program Targeted Oncology, , https://hal.sorbonne-universite.fr/hal-03198137v1
- Camille-Charlotte Balança, Clara-Maria Scarlata, Marie Michelas, Christel Devaud, Victor Sarradin, Camille Franchet, Carlos Martinez Gomez, Carlos Gomez-Roca, Marie Tosolini, Diana Heaugwane, Françoise Lauzéral-Vizcaino, Lucile Mir-Mesnier, Virginie Féliu, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Stéphanie Motton, Yann Tanguy Le Gac, Agnès Dupret Bories, Jérôme Sarini, Benjamin Vairel, Claire Illac, Aurore Siegfried-Vergnon, Eliane Mery, Jean-Jacques Fournié, Sébastien Vergez, Jean-Pierre Delord, Philippe Rochaix, Alejandra Martinez, Maha Ayyoub 2020. Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies Cancer Immunology Research, 8, pp.869-882, https://hal.science/hal-03203330v1
- Camille-Charlotte Balança # 1 , Clara-Maria Scarlata # 1 , Marie Michelas # 1 , Christel Devaud 1 , Victor Sarradin 1 2 , Camille Franchet 3 4 , Carlos Martinez Gomez 1 5 , Carlos Gomez-Roca 1 2 , Marie Tosolini 6 , Diana Heaugwane 7 , Françoise Lauzéral-Vizcaino 1 4 , Lucile Mir-Mesnier 8 , Virginie Féliu 1 , Carine Valle 6 , Frédéric Pont 6 , Gwénaël Ferron 5 , Laurence Gladieff 2 , Stéphanie Motton 9 , Yann Tanguy Le Gac 9 , Agnès Dupret-Bories 5 , Jérôme Sarini 5 , Benjamin Vairel 9 , Claire Illac 7 , Aurore Siegfried-Vergnon 3 , Eliane Mery 7 , Jean-Jacques Fournié 1 , Sébastien Vergez 4 9 , Jean-Pierre Delord 1 2 4 , Philippe Rochaix 7 , Alejandra Martinez 1 5 , Maha Ayyoub 2020. Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies Cancer Immunol Res, 8(7):869-882, https://pubmed.ncbi.nlm.nih.gov/32295784/
- Christophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, Valerie Cristina, Edith Borcoman, Eric Deutsch, Rastislav Bahleda, Valentin Calugaru, Anouchka Modesto, Elisabeth Rouits, Kathrin Gollmer, Gregoire Vuagniaux, Philippa Crompton, Claudio Zanna, Sergio Szyldergemajn, Jean-Pierre Delord, Jean Bourhis 2020. Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Clinical Cancer Research, 26, pp.6429-6436, https://hal.science/hal-04525145v1
- Anne Laprie, Soléakhéna Ken, Thomas Filleron, Vincent Lubrano, Laure Vieillevigne, Fatima Tensaouti, Isabelle Catalaa, Sergio Boetto, Jonathan Khalifa, Justine Attal, Guillaume Peyraga, Carlos Gomez-Roca, Emmanuelle Uro-Coste, Georges Noel, Gilles Truc, Marie-Pierre Sunyach, Nicolas Magné, Marie Charissoux, Stéphane Supiot, Valérie Bernier, Muriel Mounier, Muriel Poublanc, Amandine Fabre, Jean-Pierre Delord, Elizabeth Cohen-Jonathan Moyal 2019. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging BMC Cancer, 19, pp.167, https://hal.science/hal-04706298v1
- C A Gomez-Roca 1 , A Italiano 2 , C Le Tourneau 3 , P A Cassier 4 , M Toulmonde 5 , S P D'Angelo 6 , M Campone 7 , K L Weber 8 , D Loirat 9 , M A Cannarile 10 , A-M Jegg 10 , C Ries 10 , R Christen 11 , G Meneses-Lorente 12 , W Jacob 10 , I Klaman 10 , C-H Ooi 11 , C Watson 13 , K Wonde 11 , B Reis 11 , F Michielin 11 , D Rüttinger 10 , J-P Delord 9 , J-Y Blay 14 2019. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages Ann Oncol, 2019 Aug 1;30(8):1381-1392, https://pubmed.ncbi.nlm.nih.gov/31114846/
- Sandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, Jaafar Bennouna, Mouna Sassi, Helene de Mont-Serrat, Jean Fan, David Schnell, Jean-Pierre Delord 2018. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors Investigational New Drugs, 36, pp.1044-1059, https://u-bourgogne.hal.science/hal-01960201v1
- Nicolas Martin, Nicolas Isambert, Carlos Gomez-Roca, Rainer-Georg Goeldner, Sylvie Zanetta, Behbood Sadrolhefazi, Helene de Mont-Serrat, Mario Campone, Jean-Pierre Delord 2018. Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer Cancer Chemotherapy and Pharmacology, 82, pp.979-986, https://hal.science/hal-01945256v1
- Jonathan Khalifa, Fatima Tensaouti, Jean-Albert Lotterie, Isabelle Catalaa, Leonor Chaltiel, Alexandra Benouaich-Amiel, Carlos Gomez-Roca, Georges Noël, Gilles Truc, Patrice Péran, Isabelle Berry, Marie-Pierre Sunyach, Marie Charissoux, Corinne Johnson, Elizabeth Cohen-Jonathan Moyal, Anne Laprie 2016. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation? Journal of Neuro-Oncology, 130, pp.181--192, https://hal.science/hal-02342064v1
- Virginie Prulière-Escabasse, Carlos Gomez-Roca, Estelle Escudier, André Coste, Benjamin Besse, Christophe Massard, Jean-Charles Soria 2010. Rhinitis in Patients Treated with a Combination of an mTOR Inhibitor and an EGFR Inhibitor Onkologie, 33, pp.401-402, https://inserm.hal.science/inserm-04144647v1

Langues Vivantes : Anglais C2 - Courant - Espagnol C2 - Maternel - Français C2 - Maternel

Dernière mise à jour le 17 octobre 2024